CSIMarket
 


Qilian International Holding Group Limited  (QLI)
Other Ticker:  
 

Cumulative Qilian International Holding Group Limited's Total Debt to Equity for Trailing Twelve Months Period

QLI's Total Debt to Equity for Trailing Twelve Months Period and Total Debt, Equity growth


Select the Comparisons : Select the Ratio:

QLI Total Debt to Equity for Trailing Twelve Months Period

(Sep 30 2023)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Sep 30 2022)
IV. Quarter
Y / Y Equity Growth -19.31 % -19.31 % -19.31 % -19.31 % -3.01 %
Y / Y Total Debt Growth 241.24 % 241.24 % 241.24 % 241.24 % -98.21 %
Total Debt to Equity for Trailing Twelve Months Period 0.01 0.01 0.01 0 0
Total Ranking # 138 # # # # 86
Seq. Equity Growth 0 % 0 % 0 % -19.31 % 0 %
Seq. Total Debt Growth 0 % 0 % 0 % 241.24 % 0 %


Total Debt to Equity for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Due to repayements of liabilities of 0% Qilian International Holding Group Limited has not changed Total Debt to Equity for Trailing Twelve Months Period in the IV. Quarter to 0.01, below company's average Total Debt to Equity for Trailing Twelve Months Period.
Total Debt to Equity for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies in Major Pharmaceutical Preparations industry 10 other companies have achieved lower Total Debt to Equity for Trailing Twelve Months Period than Qilian International Holding Group Limited. While total ranking remained unchanged compare to previous quarter at no. .

What is Debt to Equity Ratio?
QLI Charts and Quotes
Total Debt to Equity QLI in the most recent quarter
Total Debt to Equity for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 11
Sector # 36
S&P 500 # 137


Total Debt to Equity for Trailing Twelve Months Period Statistics
High Average Low
0.14 0.07 0
(Sep 30 2021)   (Sep 30 2022)




Companies with similar average Total Debt to Equity for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Total Debt to Equity for Trailing Twelve Months Period
Alx Oncology Holdings Inc  0.03 
Cns Pharmaceuticals Inc   0.03 
Altimmune Inc   0.02 
Pliant Therapeutics Inc   0.02 
Vistagen Therapeutics Inc   0.02 
Oragenics Inc   0.02 
Puretech Health Plc  0.02 
Tenax Therapeutics Inc   0.02 
Salarius Pharmaceuticals inc   0.01 
Kura Oncology Inc   0.01 
Hookipa Pharma inc   0.01 
Shuttle Pharmaceuticals Holdings Inc   0.01 
Igc Pharma Inc   0.01 
Alpine Immune Sciences Inc   0.01 
Qilian International Holding Group Limited  0.01 
Immuron Limited  0.01 
I mab  0.01 
Nature s Sunshine Products inc   0.01 
Theriva Biologics inc 0.00 
Integrated Biopharma Inc 0.00 
Genelux Corporation 0.00 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com